Authors
Zhuo Chen, Lin Shi, Junjie Lu, Jing Su
Published in
Mediators of inflammation. Volume 2026. Issue 1. Pages e2700500.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent. Life's Crucial 9 (LC9) combines cardiometabolic and mental health metrics linked to MASLD pathogenesis, but its association with liver fibrosis and prognosis in MASLD remains unknown.
Using National Health and Nutrition Examination Survey (NHANES) data, we performed a prospective cohort analysis for mortality (2005-2016, n = 2524) and a cross-sectional analysis for liver fibrosis (2017-2018, n = 1277). Significant fibrosis was defined as liver stiffness measurement (LSM) ≥8.0 kPa by vibration-controlled transient elastography. Systemic inflammation was assessed using the systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV). Multivariable regression and mediation analyses were conducted.
Higher LC9 scores were associated with lower liver stiffness (β = -0.07, 95% CI: -0.12 to -0.01). Each 1-point increase in LC9 reduced fibrosis risk by 5% (OR = 0.95), with the highest quartile showing the lowest risk (OR = 0.21). Over a median follow-up of 98 months, each 1-point LC9 increase was associated with a 3% reduction in all-cause mortality (HR = 0.97). Lower systemic inflammation partially mediated the LC9-mortality relationship (SII: 5%, PIV: 6.3%).
Higher LC9 scores are associated with reduced liver fibrosis and improved survival in MASLD, with systemic inflammation partially mediating the mortality association.
PMID:
42318783
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0